Journal
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
Volume 36, Issue 1, Pages 707-718Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/14756366.2021.1892089
Keywords
Histone deacetylase; inhibitor; anticancer; phenanthridine; linker
Funding
- Natural Foundation of Shandong Province [ZR2019QH005, ZR2019BH068]
- Science and Technology Support Plan for Youth Innovation in Universities of Shandong Province [2019KJM001]
- National Natural Science Foundation of China [81803343, 81903468]
Ask authors/readers for more resources
In this study, pharmacophores of phenanthridine were incorporated into HDAC inhibitors, and fatty and aromatic linkers were evaluated for solubility and activity. Compounds with aromatic linker showed better activities than those with fatty linker. Molecule Fb-4 exhibited promising anticancer potency by inducing G2/M phase arrest and apoptosis in MCF-7 cells, suggesting its potential as a lead compound for further drug design.
In discovery of novel HDAC inhibitory with anticancer potency, pharmacophores of phenanthridine were introduced to the structure of HDAC inhibitors. Fatty and aromatic linkers were evaluated for their solubility and activity. Both enzyme inhibitory and in vitro antiproliferative (against U937 cells) screening results revealed better activities of compounds with aromatic linker than molecules with fatty linker. Compared with SAHA (IC50 values of 1.34, 0.14, 2.58, 0.67 and 18.17 mu M), molecule Fb-4 exhibited 0.87, 0.09, 0.32, 0.34 and 17.37 mu M of IC50 values against K562, U266, MCF-7, U937 and HEPG2 cells, respectively. As revealed by cell cycle and apoptotic analysis, induction of G2/M phase arrest and apoptosis plays an important role in the inhibition of MCF-7 cells by Fb-4. Generally, a potent HDAC inhibitor was developed in the present study which could be utilised as a lead compound for further anticancer drug design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available